logo
Plus   Neg
Share
Email

Pfizer, IDEAYA To Evaluate Clinical Combination Of IDE196 & Binimetinib

IDEAYA Biosciences, Inc. (IDYA) has entered into a clinical trial collaboration and supply agreement with Pfizer Inc. (PFE) for a clinical combination study of IDE196, and binimetinib, in GNAQ or GNA11 hotspot mutated solid tumors. IDEAYA will sponsor the study. Pfizer will supply binimetinib for the study. The trial is expected to begin in mid-2020.

"The prevalence of GNAQ or GNA11 hotspot mutations in Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, and other solid tumors represents approximately 6,000 patients in the U.S. and the five major European countries, and there are no approved targeted therapies for MUM or GNAQ/GNA11 hotspot mutation solid tumors," said Yujiro Hata, CEO, IDEAYA Biosciences.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apotex Corp. recalled all lots of type 2 diabetes medication Metformin hydrochloride in the form of oral film-coated tablets for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine (NDMA), above levels of the Acceptable Daily Intake Limit (ADI), the U.S. Food and Drug Administration or FDA said in a statement. Groupe Renault plans to cut about 14,600 jobs across the world and lower its production capacity. The plan includes almost 4,600 jobs reduction in France, through voluntary retirement and retraining. Amazon said it will convert 125,000 of the 175,000 temporary workers it hired in March amid the coronavirus pandemic, to permanent full-time employees in June. The e-commerce giant had hired the temporary employees in March to meet strong consumer demand amid the lockdown. The job openings were in Amazon's fulfillment centers and its delivery network.
Follow RTT